RT Journal Article
SR Electronic
T1 Agent-based Investigation of the Impact of Low Rates of Influenza on Next Season Influenza Infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.18.21262185
DO 10.1101/2021.08.18.21262185
A1 Krauland, Mary G
A1 Galloway, David D
A1 Raviotta, Jonathan M
A1 Zimmerman, Richard K
A1 Roberts, Mark S
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.18.21262185.abstract
AB Introduction Interventions to curb the spread of SARS-CoV-2 during the 2020-21 influenza season essentially eliminated influenza during that season. Given waning antibody titers over time, future residual population immunity against influenza will be reduced. The implication for the subsequent 2021-22 influenza season is unknown.Methods We used an agent-based model of influenza implemented in the FRED (Framework for Reconstructing Epidemiological Dynamics) simulation platform to estimate cases and hospitalization over two succeeding influenza seasons. The model uses a synthetic population to represent an actual population, and individual interactions in workplaces, school, households and neighborhoods. The impact of reduced residual immunity was estimated as a consequence of increased protective measures (e.g., social distancing and school closure) in the first season. The impact was contrasted by the level of similarity (cross-immunity) between influenza strains over the seasons.Results When the second season strains were dissimilar to the first season (have a low level of cross immunity), a low first season has limited impact on second season cases. When a high level of cross-immunity exists between strains in the 2 seasons, the first season has a much greater impact on the second season. In both cases this is modified by the transmissibility of strains in the 2 seasons. In the context of the 2021-22 season, the worst case scenario is a highly transmissible strain causing increased cases and hospitalizations over average influenza seasons, with a possible significant increase in cases in some scenarios. The most likely overall scenario for 2021-22 is a more modest increase in flu cases over an average season.Discussion Given the light 2020-21 season, we found that a large, compensatory second season might occur in 2021-22, depending on cross-immunity from past infection and transmissibility of strains. Furthermore, we found that enhanced vaccine coverage could reduce this high, compensatory season. Young children may be especially at risk in 2021-22 since very young children were unlikely to have had any exposure to infection and most immunity in that age group would be from vaccination, which wanes quickly.Competing Interest StatementDrs. Zimmerman and Raviotta have research grant funding from Sanofi Pasteur on an unrelated vaccine topic.Clinical Trialn/aFunding StatementThis work was supported by the Center for Disease Control and Prevention U01-IP001141-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Pittsburgh IRB has determined that this study was not human subject research and is therefore exempt.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is publicly available.